Search

Your search keyword '"Maurer, Harold M."' showing total 319 results
Start Over Author "Maurer, Harold M."
319 results on '"Maurer, Harold M."'

104. The intergroup rhabdomyosarcoma study-I.A final report

Author

Maurer, Harold M., primary, Crist, William, additional, Lawrence, Walter, additional, Ragab, Abdelsalam H., additional, Raney, R. Beverly, additional, Webber, Bruce, additional, Wharam, Moody, additional, Vietti, Teresa J., additional, Beltangady, Mohan, additional, Gehan, Edmund A., additional, Hammond, Denman, additional, Hays, Daniel M., additional, Heyn, Ruth, additional, Newton, William, additional, Ortega, Jorge, additional, Ruymann, Frederick B., additional, Soule, Edward, additional, and Tefft, Melvin, additional

Published
1988
Full Text
View/download PDF

114. Rhabdomyosarcoma in childhood and adolescence

Author

Maurer, Harold M., primary, Donaldson, Milton, additional, Gehan, Edmund A., additional, Hammond, Denman, additional, Hays, Daniel M., additional, Lawrence, Walter, additional, Lindberg, Robert, additional, Moon, Thomas, additional, Newton, William, additional, Ragab, Abdelsalam, additional, Raney, Beverly, additional, Ruymann, Frederick, additional, Soule, Edward H., additional, Sutow, W.W., additional, and Tefft, Melvin, additional

Published
1978
Full Text
View/download PDF

126. The intergroup rhabdomyosarcoma study.A preliminary report

Author

Maurer, Harold M., primary, Moon, Thomas, additional, Donaldson, Milton, additional, Fernandez, Carlos, additional, Gehan, Edmund A., additional, Hammond, Denman, additional, Hays, Daniel M., additional, Lawrence, Walter, additional, Newton, William, additional, Ragab, Abdelsalam, additional, Raney, Beverly, additional, Soule, Edward H., additional, Sutow, W. W., additional, and Tefft, Melvin, additional

Published
1977
Full Text
View/download PDF

142. Pediatric Orofacial and Laryngopharyngeal Rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma Study Report

Author

Wharam, Moody D., Beltangady, Mohan S., Heyn, Ruth M., Lawrence, Walter, Raney, R. Beverly, Ruymann, Frederick B., Soule, Edward H., Tefft, Melvin, and Maurer, Harold M.

Abstract

• Eighty-nine children with localized rhabdomyosarcoma of orofacial and laryngopharyngeal sites were treated in accordance with the first and second Intergroup Rhabdomyosarcoma Study (IRS) protocols (IRS-I and IRS-II) between 1972 and 1984. Treatment included surgery (or biopsy) and chemotherapy for all patients and radiotherapy in the majority. The actuarial estimate of the three-year survival rate for all patients was 83% and did not differ significantly by primary site, histologic findings, or presence of adenopathy. A trend for a worse survival rate was seen in clinical group III patients and in those less than 5 years of age at diagnosis. Factors associated with an increased risk of local/regional relapse included omission of radiotherapy and a radiation dose of less than 40 Gy (4000 rad). We conclude that treatment of these patients as recommended in the IRS-I and IRS-II protocols results in very good local and regional tumor control and survival rates. Salvage therapy for local/regional recurrence may yield long-term remission and possibly cure.(Arch Otolaryngol Head Neck Surg 1987;113:1225-1227)

Published
1987
Full Text
View/download PDF

144. The Growing Neglect of American Children

Author

Maurer, Harold M.

Abstract

America is not doing enough to meet the health care needs of poor children. Unless we face up to this growing neglect, our nation's future is in doubt. Although we frequently hear that "children are our greatest national resource," we see little evidence to indicate that our policy makers believe it or are willing to act to prevent the terrible waste in human resources as a result of poverty. The money spent on health care for the elderly in America is 15 times that spent on health care for children.1 Although children represent 50% of the Medicaid population, they receive less than 20% of the money spent for health services.1 Furthermore, Medicaid reimbursement for health services for children is so low that few physicians in private practice can afford to see Medicaid patients.The facts regarding impoverished children are staggering. They are cause for concern regarding the values

Published
1991
Full Text
View/download PDF

147. Report of the Cancer Therapy Evaluation Program Monitoring Plan for Secondary Acute Myeloid Leukemia Following Treatment With Epipodophyllotoxins

Author

Smith, Malcolm A., Rubinstein, Lawrence, Cazenave, Lorraine, Ungerleider, Richard S., Maurer, Harold M., Heyn, Ruth, Khan, Farced M., and Gehan, Edmund

Abstract

Background: Recent reports have documented the occurrence of treatment-related acute myeloid leukemia (AML) following therapy with epipodophyllotoxins. These reports have led to growing concern among oncologists, which could lead to premature abandonment of these agents at a time when the relationship between cumulative dose of epipo-dophyllotoxin and risk of treatment-related AML has not been determined. Purpose: Because of the increasingly important role of epipodophyllotoxins in the treatment of several types of adult and pediatric tumors, the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) has developed a monitoring plan to obtain reliable estimates of the risk of treatment-related AML following epipodophyl-lotoxin treatment. Methods: We identified 12 NCI-supported Cooperative Group clinical trials in which patients with solid tumors are being treated with epipodophyllotoxins at different cumulative doses. One trial is using a moderate dose of teni-poside (900 mg/m2), and 11 trials are using etoposide at a low dose (<1500 mg/m2), a moderate dose (1500-3999 mg/m2), or a high dose (≥4000 mg/m2). Cases of treatment-related AML and treatment-related myelo-dysplastic syndrome (MDS) (hereafter referred to as treatment-related AML/MDS) occurring in these trials are reported to CTEP, with initial analysis for each cumulative dose group triggered by the reporting of four cases of treatment-related AML/MDS in that group. For each analysis, total patient follow-up for the group is determined and cumulative 6-year incidence rate is calculated. Results: Three cases of treatment-related AML and one case of treatment-related MDS (with documented monosomy 7) were reported in a group of 207 patients who received etoposide at a low cumulative dose. The calculated 6-year rate of development of treatment-related AML/MDS was 3.2% (95% upper confidence interval bounded by 7.2%). Conclusions: The 6-year cumulative rate of treatment-related AML/MDS (3.2%) is within the range previously reported for alkylator-based regimens that did not include epipodophyllotoxins. Implications: Previous reports have suggested that higher cumulative doses of alkylators are associated with increased risk of treatment-related AML, and a critical goal of the monitoring plan is to determine whether a similar relationship exists for the epipodophyllotoxins. Estimates will be developed for leuke-mogenic risk for the moderate- and high-cumulative-dose groups when four cases of treatment-related AML/MDS have been identified within each group.

Published
1993
Full Text
View/download PDF

150. ADVANCED CHILDHOOD RHABDOMYOSARCOMA

Author

Raney, R. Beverly, Donaldson, Milton H., Maurer, Harold M., Newton, William A., Ragab, Abdelsalam H., Ruymann, Frederick B., and Sutow, Wataru W.

Published
1978

Catalog

Books, media, physical & digital resources
See catalog results